Document Detail

Effects of hormone therapy on blood pressure and the renin-angiotensin system in postmenopausal women.
MedLine Citation:
PMID:  17653023     Owner:  NLM     Status:  MEDLINE    
Observational studies have documented an association between lower rates of cardiovascular disease and hormone therapy (HT). Meanwhile, randomized clinical trials have documented increased rates of myocardial infarction and stroke in women receiving hormone therapy. These seemingly discordant findings have stimulated new research to examine estrogen's effects on the cardiovascular system, including its effects on blood pressure, regulation of the renin-angiotensin system (RAS), and the clinical consequences of hypertension. In the last 6 years several studies have better defined the mechanisms by which HT affect the RAS, blood pressure, and the clinical effects of hypertension. Recent studies documented increases in angiotensinogen synthesis and the suppression of active renin with estrogen replacement. Genotype may be a factor in determining the degree of suppression of angiotensin converting enzyme levels that occurs with estrogen therapy. Estrogen supplementation in postmenopausal women increases systemic angiotensin II, a potent vasoconstrictor. This vasopressor effect is attenuated by an estrogen-induced reduction of angiotensin II type 1 receptor expression. Renal blood flow reduction, in the absence of blood pressure changes, have been reported after estrogen replacement, and an increased risk of total stroke has been demonstrated in hypertensive women on HT compared to normotensive women on this therapy. Estrogen replacement affects many components of the RAS, but its effect on this system has little effect on blood pressure. Further studies are needed to describe the effects of estrogen replacement on abnormal vasculature and how these effects relate to myocardial infarction and stroke.
D D Prime; K B Brosnihan; D M Herrington
Related Documents :
15466263 - Intravenous delivery of pth/pthrp type 1 receptor cdna to rats decreases heart rate, bl...
205983 - The immediate pressor response to saralasin: a measure of the degree of angiotensin ii ...
12722033 - Relationships between renovascular disease, blood pressure, and renal function in the e...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  55     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-07-26     Completed Date:  2008-02-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  477-85     Citation Subset:  IM    
Cardiology Section, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II / metabolism
Angiotensinogen / biosynthesis,  drug effects
Blood Pressure / drug effects*
Estrogen Replacement Therapy* / adverse effects
Renal Circulation / drug effects*
Renin / drug effects,  metabolism
Renin-Angiotensin System / drug effects*
Risk Factors
Reg. No./Substance:
11002-13-4/Angiotensinogen; 11128-99-7/Angiotensin II; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Radiofrequency minimally invasive endovascular treatment of lower limbs varicose veins: clinical exp...
Next Document:  The metabolic syndrome is no better than its components.